www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

US EUROPE AFRICA ASIA 中文
Business / Industries

Stem cells offer ray of hope for healthy future

By Alfred Romann in Seoul For China Daily (China Daily) Updated: 2014-06-23 07:08

Regenerative medicine sector needs more financial support from private investors

One of the most important and innovative pharmaceutical companies in Asia has its headquarters in a busy neighborhood of Seoul, nestled between insurance companies and banks, and not far from Seoul National University.

Medipost Co Ltd, launched in 2000 to research and develop stem cell and regenerative medicine products, has emerged as a leader in the space, both regionally and globally. It took a dozen years for the company to launch its first product commercially: Cartistem used to treat repair cartilages in the knee.

Between its founding and its first product launch, Medipost issued new shares six times and split its stock once. It generated some further revenue, mostly by storing umbilical cord blood, using the blood to transplant stem cells, and later by out-licensing products.

But that income was tiny compared to the cost of developing its drugs. Improbably, it managed to attract enough investors to keep going and growing.

That investment is now starting to pay off. Cartistem is just one of three stem cell products approved for sale in South Korea, and Medipost might be the only public company in the country with global ambitions.

"There are not many companies that can deal with global development in the pharmerging market," said Jay Lee, a senior director at Medipost, speaking at a conference in South Korea last month.

The "pharmerging" markets are the emerging markets for pharmaceutical products. China is possibly the biggest, but there are quite a few of them in the region including South Korea and much of the Association of Southeast Asian Nations.

Even Japan, despite its large economy, is considered an emerging market in some ways because it is often years before drugs developed elsewhere make their way down to patients there due to conservative regulations.

But much is changing in the region, particularly in South Korea and Japan. Both countries are embracing often-controversial research into regenerative medicine, including stem cells.

"There is an exceptional example of a new approach in Japan. They are looking very much, as in South Korea, to develop the stem cell space," says Dianne Jackson-Matthews, an Australia-based director at ERA Consulting Group.

For the time being, government support is driving the growth of this particular industry. Private or institutional investors are not yet convinced that taking a risk on a company developing a drug using science few people understand is worthwhile.

Stem cells offer ray of hope for healthy future

Stem cells offer ray of hope for healthy future

 Stem Cell Industrial Park under construction in Wenjiang  Medical experts call for effective stem cell treatment regulation

Previous Page 1 2 3 Next Page

Hot Topics

Editor's Picks
...
...
主站蜘蛛池模板: 欧美精品一二三区 | 香港黄页亚洲一级 | av在线天堂网 | 日本乱子伦xxxx | 黄色三级理沦片 | 久久精品国产影库免费看 | 日韩一区二区三 | 盈盈性影院 | 9191精品国产费久久 | 国产精品高清在线观看地址 | 国产步兵社区视频在线观看 | 最新国产三级久久 | 久久99爰这里有精品国产 | 亚洲视频观看 | 2019偷偷狠狠的日日 | 天天综合天天看夜夜添狠狠玩 | 国产精品亚洲综合网站 | 久久亚洲国产视频 | 99免费在线观看 | 美女网站免费观看视频 | 精品国产免费一区二区三区 | 在线播放高清国语自产拍免费 | 香蕉久久精品 | 性欧美精品久久久久久久 | 久久国产视屏 | 一级毛片免费观看不卡视频 | 国产三级做爰高清在线 | 久久高清影院 | 亚洲国产第一区二区三区 | 欧美日韩国产亚洲一区二区三区 | 久久成人性色生活片 | 大胆gogo999亚洲肉体艺术 | 一区在线观看 | 国产成人一区二区三区 | 成年女人永久免费观看片 | 欧美大片在线观看成人 | 亚洲精品乱无伦码 | 老司机亚洲精品影院在线 | 被老外玩爽的中国美女视频 | 亚洲精品国产一区二区三区在 | www.亚洲免费 |